Cargando…
Partnered implementation of the veteran sponsorship initiative: protocol for a randomized hybrid type 2 effectiveness—implementation trial
BACKGROUND: The USA is undergoing a suicide epidemic for its youngest Veterans (18-to-34-years-old) as their suicide rate has almost doubled since 2001. Veterans are at the highest risk during their first-year post-discharge, thus creating a “deadly gap.” In response, the nation has developed strate...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264302/ https://www.ncbi.nlm.nih.gov/pubmed/35804354 http://dx.doi.org/10.1186/s13012-022-01212-9 |
_version_ | 1784742947592339456 |
---|---|
author | Geraci, Joseph C. Finley, Erin P. Edwards, Emily R. Frankfurt, Sheila Kurz, A. Solomon Kamdar, Nipa Vanneman, Megan E. Lopoo, Leonard M. Patnaik, Hannah Yoon, Jean Armstrong, Nicholas Greene, Ashley L. Cantor, Gilly Wrobleski, Joseph Young, Erin Goldsmith, Matthew Seim, Richard W. Goodman, Marianne |
author_facet | Geraci, Joseph C. Finley, Erin P. Edwards, Emily R. Frankfurt, Sheila Kurz, A. Solomon Kamdar, Nipa Vanneman, Megan E. Lopoo, Leonard M. Patnaik, Hannah Yoon, Jean Armstrong, Nicholas Greene, Ashley L. Cantor, Gilly Wrobleski, Joseph Young, Erin Goldsmith, Matthew Seim, Richard W. Goodman, Marianne |
author_sort | Geraci, Joseph C. |
collection | PubMed |
description | BACKGROUND: The USA is undergoing a suicide epidemic for its youngest Veterans (18-to-34-years-old) as their suicide rate has almost doubled since 2001. Veterans are at the highest risk during their first-year post-discharge, thus creating a “deadly gap.” In response, the nation has developed strategies that emphasize a preventive, universal, and public health approach and embrace the value of community interventions. The three-step theory of suicide suggests that community interventions that reduce reintegration difficulties and promote connectedness for Veterans as they transition to civilian life have the greatest likelihood of reducing suicide. Recent research shows that the effectiveness of community interventions can be enhanced when augmented by volunteer and certified sponsors (1-on-1) who actively engage with Veterans, as part of the Veteran Sponsorship Initiative (VSI). METHOD/DESIGN: The purpose of this randomized hybrid type 2 effectiveness-implementation trial is to evaluate the implementation of the VSI in six cities in Texas in collaboration with the US Departments of Defense, Labor and Veterans Affairs, Texas government, and local stakeholders. Texas is an optimal location for this large-scale implementation as it has the second largest population of these young Veterans and is home to the largest US military installation, Fort Hood. The first aim is to determine the effectiveness of the VSI, as evidenced by measures of reintegration difficulties, health/psychological distress, VA healthcare utilization, connectedness, and suicidal risk. The second aim is to determine the feasibility and potential utility of a stakeholder-engaged plan for implementing the VSI in Texas with the intent of future expansion in more states. The evaluators will use a stepped wedge design with a sequential roll-out to participating cities over time. Participants (n=630) will be enrolled on military installations six months prior to discharge. Implementation efforts will draw upon a bundled implementation strategy that includes strategies such as ongoing training, implementation facilitation, and audit and feedback. Formative and summative evaluations will be guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework and will include interviews with participants and periodic reflections with key stakeholders to longitudinally identify barriers and facilitators to implementation. DISCUSSION: This evaluation will have important implications for the national implementation of community interventions that address the epidemic of Veteran suicide. Aligned with the Evidence Act, it is the first large-scale implementation of an evidence-based practice that conducts a thorough assessment of TSMVs during the “deadly gap.” TRIAL REGISTRATION: ClinicalTrials.gov ID number: NCT05224440. Registered on 04 February 2022. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13012-022-01212-9. |
format | Online Article Text |
id | pubmed-9264302 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-92643022022-07-08 Partnered implementation of the veteran sponsorship initiative: protocol for a randomized hybrid type 2 effectiveness—implementation trial Geraci, Joseph C. Finley, Erin P. Edwards, Emily R. Frankfurt, Sheila Kurz, A. Solomon Kamdar, Nipa Vanneman, Megan E. Lopoo, Leonard M. Patnaik, Hannah Yoon, Jean Armstrong, Nicholas Greene, Ashley L. Cantor, Gilly Wrobleski, Joseph Young, Erin Goldsmith, Matthew Seim, Richard W. Goodman, Marianne Implement Sci Study Protocol BACKGROUND: The USA is undergoing a suicide epidemic for its youngest Veterans (18-to-34-years-old) as their suicide rate has almost doubled since 2001. Veterans are at the highest risk during their first-year post-discharge, thus creating a “deadly gap.” In response, the nation has developed strategies that emphasize a preventive, universal, and public health approach and embrace the value of community interventions. The three-step theory of suicide suggests that community interventions that reduce reintegration difficulties and promote connectedness for Veterans as they transition to civilian life have the greatest likelihood of reducing suicide. Recent research shows that the effectiveness of community interventions can be enhanced when augmented by volunteer and certified sponsors (1-on-1) who actively engage with Veterans, as part of the Veteran Sponsorship Initiative (VSI). METHOD/DESIGN: The purpose of this randomized hybrid type 2 effectiveness-implementation trial is to evaluate the implementation of the VSI in six cities in Texas in collaboration with the US Departments of Defense, Labor and Veterans Affairs, Texas government, and local stakeholders. Texas is an optimal location for this large-scale implementation as it has the second largest population of these young Veterans and is home to the largest US military installation, Fort Hood. The first aim is to determine the effectiveness of the VSI, as evidenced by measures of reintegration difficulties, health/psychological distress, VA healthcare utilization, connectedness, and suicidal risk. The second aim is to determine the feasibility and potential utility of a stakeholder-engaged plan for implementing the VSI in Texas with the intent of future expansion in more states. The evaluators will use a stepped wedge design with a sequential roll-out to participating cities over time. Participants (n=630) will be enrolled on military installations six months prior to discharge. Implementation efforts will draw upon a bundled implementation strategy that includes strategies such as ongoing training, implementation facilitation, and audit and feedback. Formative and summative evaluations will be guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework and will include interviews with participants and periodic reflections with key stakeholders to longitudinally identify barriers and facilitators to implementation. DISCUSSION: This evaluation will have important implications for the national implementation of community interventions that address the epidemic of Veteran suicide. Aligned with the Evidence Act, it is the first large-scale implementation of an evidence-based practice that conducts a thorough assessment of TSMVs during the “deadly gap.” TRIAL REGISTRATION: ClinicalTrials.gov ID number: NCT05224440. Registered on 04 February 2022. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13012-022-01212-9. BioMed Central 2022-07-08 /pmc/articles/PMC9264302/ /pubmed/35804354 http://dx.doi.org/10.1186/s13012-022-01212-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Geraci, Joseph C. Finley, Erin P. Edwards, Emily R. Frankfurt, Sheila Kurz, A. Solomon Kamdar, Nipa Vanneman, Megan E. Lopoo, Leonard M. Patnaik, Hannah Yoon, Jean Armstrong, Nicholas Greene, Ashley L. Cantor, Gilly Wrobleski, Joseph Young, Erin Goldsmith, Matthew Seim, Richard W. Goodman, Marianne Partnered implementation of the veteran sponsorship initiative: protocol for a randomized hybrid type 2 effectiveness—implementation trial |
title | Partnered implementation of the veteran sponsorship initiative: protocol for a randomized hybrid type 2 effectiveness—implementation trial |
title_full | Partnered implementation of the veteran sponsorship initiative: protocol for a randomized hybrid type 2 effectiveness—implementation trial |
title_fullStr | Partnered implementation of the veteran sponsorship initiative: protocol for a randomized hybrid type 2 effectiveness—implementation trial |
title_full_unstemmed | Partnered implementation of the veteran sponsorship initiative: protocol for a randomized hybrid type 2 effectiveness—implementation trial |
title_short | Partnered implementation of the veteran sponsorship initiative: protocol for a randomized hybrid type 2 effectiveness—implementation trial |
title_sort | partnered implementation of the veteran sponsorship initiative: protocol for a randomized hybrid type 2 effectiveness—implementation trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264302/ https://www.ncbi.nlm.nih.gov/pubmed/35804354 http://dx.doi.org/10.1186/s13012-022-01212-9 |
work_keys_str_mv | AT geracijosephc partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial AT finleyerinp partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial AT edwardsemilyr partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial AT frankfurtsheila partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial AT kurzasolomon partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial AT kamdarnipa partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial AT vannemanmegane partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial AT lopooleonardm partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial AT patnaikhannah partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial AT yoonjean partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial AT armstrongnicholas partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial AT greeneashleyl partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial AT cantorgilly partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial AT wrobleskijoseph partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial AT youngerin partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial AT goldsmithmatthew partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial AT seimrichardw partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial AT goodmanmarianne partneredimplementationoftheveteransponsorshipinitiativeprotocolforarandomizedhybridtype2effectivenessimplementationtrial |